AJANTPHARM

** Shares of Ajanta Pharma AJPH.NS rise 4.15% to 2735.45 rupees

** Stock rises after the specialty pharmaceutical company announced its plans to expand manufacturing capabilities to meet growing global demand

** AJPH to add a liquid formulation facility at its Pithampur site in Madhya Pradesh

** Facility to boost capacity to 12 million bottles per annum, from the current 6 million bottles

** AJPH says the capacity expansion will require an investment of 920 million rupees ($10.66 million)

** AJPH shares are down 7.1% so far in 2025, against an 8% fall in the pharma index .NIPHARM, of which it is a constituent

($1 = 86.2650 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Jan 30 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• DEC-QUARTER CONSOL NET PROFIT 2.33 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.46 BILLION RUPEES

Source text: ID:nBSE7SQY1v

Further company coverage: AJPH.NS

(([email protected];;))

Oct 28 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA SEPT-QUARTER CONSOL NET PROFIT 2.16 BILLION RUPEES

• AJANTA PHARMA LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 11.87 BILLION RUPEES

• AJANTA PHARMA LTD - DIVIDEND 28 RUPEES PER SHARE

Source text: ID:nBSE2kT0DX

Further company coverage: AJPH.NS

(([email protected];))

** Shares of Ajanta Pharma AJPH.NS climb as much as 6.7% to a record high of 2,579.90 rupees

** Stock set for ninth straight session of gain

** Drugmaker's Q1 consol profit after tax rose 18% Y/Y; rev grew 12% Y/Y

** Mean rating of nine analysts is "buy"; median PT is 2,400 rupees - LSEG data

** Stock up 24% YTD after gaining 73% in 2023

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Ajanta Pharma AJPH.NS rise as much as 13.7% to a record high of 2,540 rupees; last up 8.7%

** Stock is the top gainer in the Nifty 500 index .NIFTY500 and is on pace for its 11th consecutive session of gains

** The specialty pharmaceuticals maker reported a 65.8% jump in its consolidated profit for the quarter ended March 31 to 2.03 bln rupees ($24.4 mln)

** Revenue from operations rose 19.5% Y/Y

** Co has also approved a buy-back of equity shares at a price of 2,770 rupees per share

** Stock posts biggest intraday pct gain since Feb. 20, 2020

** Average rating of 10 analysts covering the stock is "buy"; median PT is 2,235 rupees - LSEG data

** More than 871,000 shares change hands as of 9:52 a.m. IST, 8.1x 30-day average

** Including session's gain, stock is up 17% YTD

($1 = 83.3790 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

May 2 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA LTD - APPROVAL OF BUY-BACK OF EQUITY SHARES

• AJANTA PHARMA LTD - APPROVAL OF BUY-BACK OF EQUITY SHARES AT PRICE 2770 RUPEES PER SHARE

• AJANTA PHARMA LTD - BUY-BACK UPTO 2.85 BILLION RUPEES

• AJANTA PHARMA MARCH-QUARTER CONSOL PROFIT 2.03 BILLION RUPEES VERSUS PROFIT 1.22 BILLION RUPEES

• AJANTA PHARMA LTD - BUY-BACK THROUGH TENDER OFFER

• AJANTA PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 10.54 BILLION RUPEES VERSUS 8.82 BILLION RUPEES

Source text for Eikon: ID:nBSE8VwH6V

Further company coverage: AJPH.NS

(([email protected];))

** Shares of Ajanta Pharma AJPH.NS rise as much as 5.8% to 2,300 rupees in early trading; stock has since pared gains, now up 1.5%

** Pharma co reported a 56.1% Y/Y jump in third-quarter net profit on 13.7% increase in rev from ops

** Stock trading above its 100-day moving averages since March end

** Avg rating of 12 analysts close to equivalent of "buy;" median PT is 2,030 rupees - LSEG

** Stock on track for a fourth consecutive quarter of gains, if trend holds

(Reporting by Navamya Ganesh Acharya)

(([email protected]; +91 8805175330 ;))

Jan 31 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA DEC-QUARTER CONSOL NET PROFIT 2.10 BILLION RUPEES VERSUS PROFIT 1.35 BILLION RUPEES

• AJANTA PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.05 BILLION RUPEES VERSUS 9.72 BILLION RUPEES

• AJANTA PHARMA LTD - DIVIDEND OF 26 RUPEES PER SHARE

Source text for Eikon: [ID:]

Further company coverage: AJPH.NS

(([email protected];))

** Shares of Ajanta Pharma AJPH.NS rise 2.4% to a record high of 1,995.95 rupees

** Stock trading above its 50-, 100-, and 200-day moving averages since Nov. 1

** More than 180,000 shares change hands by 3:06 p.m. IST, 1x the 30-day avg

** Eleven analysts rate stock "buy" or higher, one "hold" and "sell"; median PT is 2030 rupees - LSEG data

** Including day's gains so far, stock up ~64.1% so far this year

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Oct 31 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• SEPT-QUARTER CONSOL NET PROFIT 1.95 BILLION RUPEES VERSUS 1.57 BILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 10.28 BILLION RUPEES VERSUS 9.38 BILLION RUPEES

Further company coverage: AJPH.NS

(([email protected];))

** Shares of specialty pharmaceuticals maker Ajanta Pharma AJPH.NS up as much as 9.37% to a record high of 1697.95 rupees

** Co on track for second consecutive session of gains if trends hold

** AJPH reported a near 19% rise in consolidated profit after tax for the quarter ended June 30 to 2.08 billion rupees ($25.3 million)

** Co approved total dividend of 25 rupees per share, which includes special dividend of 15 rupees per share

** About 388,293 shares change hands as of 9:25 a.m. IST, vs 2.5x 30-day average of 157,708 shares

** Stock up 28.1% YTD as of last close

($1 = 82.1973 Indian rupees)

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

July 27 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA JUNE-QUARTER CONSOL PAT 2.08 BILLION RUPEES VERSUS 1.75 BILLION RUPEES

• AJANTA PHARMA LTD - INTERIM DIVIDEND 25 RUPEES PER SHARE

• AJANTA PHARMA JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 10.21BLN RUPEES VERSUS 9.51 BILLION RUPEES

Source text for Eikon: ID:nBSE1Vcrdq

Further company coverage: AJPH.NS

(([email protected];))

June 26 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• US FDA INSPECTION OF OUR DAHEJ FACILITY

• AT END OF INSPECTION, NO FORM 483 WAS ISSUED

Source text for Eikon: ID:nBSE1FfsT9

Further company coverage: AJPH.NS

(([email protected];))

May 5 (Reuters) - Ajanta Pharma Ltd AJPH.NS:

• AJANTA PHARMA MARCH-QUARTER CONSOL PROFIT 1.22 BILLION RUPEES VERSUS 1.51 BILLION RUPEES

• AJANTA PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 8.82 BILLION RUPEES VERSUS 8.70 BILLION RUPEES

Source text for Eikon: ID:nBSEV7qs7

Further company coverage: AJPH.NS

(([email protected];))